Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Dezember 2025 08:00 ET | Quelle: CoRegen, Inc.

CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors

HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of solid tumor cancer,...
10. September 2025 08:00 ET | Quelle: CoRegen, Inc.

CoRegen, Inc. Strengthens Leadership Team with the Appointments of Sonja Nelson as Chief Financial Officer and Peter Gelinas as Chief Technical Officer

HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced...
31. Juli 2025 09:06 ET | Quelle: CoRegen, Inc.

CoRegen, Inc. Appoints Biotech Veteran Sonal Gupta, M.D., Ph.D., as Chief Medical Officer

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced the...
09. Juli 2025 08:00 ET | Quelle: CoRegen, Inc.

CoRegen, Inc. Closes More Than $93 Million Financing

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced...
16. November 2023 10:17 ET | Quelle: CoRegen, Inc.

CoRegen Appoints Edward J. Benz, M.D., to its Board of Directors

HOUSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, announced today the...
01. Juni 2023 10:17 ET | Quelle: CoRegen, Inc.

CoRegen Inc. Announces Publication of Preclinical Research Demonstrating Treatment with Modified Tregs Eliminates Tumors and Prevents Recurrence Without Side Effects

HOUSTON, June 01, 2023 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer and chronic diseases,...